NCT01272037: A reported trial by National Cancer Institute (NCI)
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT01272037 |
|---|---|
| Title | A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Jan. 15, 2011 |
| Completion date | Feb. 1, 2023 |
| Required reporting date | Feb. 1, 2024, midnight |
| Actual reporting date | April 25, 2023 |
| Date last checked at ClinicalTrials.gov | Feb. 9, 2024 |
| Days late | None |